AKU · Akumin Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Annual Quarterly

Income Statement

Line item	FY 2022	FY 2021	FY 2020
Revenue	$749.63M	$421.08M	$251.28M
Cost of Revenue	-	-	-
Gross Profit	-	-	-
R&D	-	-	-
SG&A	-	-	-
Total Operating Expenses	$777.71M	$408.00M	$216.44M
D&A	$98.20M	$44.90M	$20.46M
Operating Income	($28.08M)	$13.07M	$34.84M
Interest Expense	$118.01M	$62.58M	$32.78M
Income Tax	$8.41M	($30.39M)	($5.75M)
Net Income	($156.76M)	($43.29M)	($20.40M)
EPS - Basic	($0.56)	-	-
EPS - Diluted	($0.56)	-	-

Balance Sheet

Line item	FY 2022	FY 2021	FY 2020
Cash & Equivalents	$59.42M	$48.42M	$19.33M
Accounts Receivable	$114.17M	$121.53M	$82.87M
Inventory	-	-	-
Accounts Payable	$36.62M	-	$21.71M
Current Assets	$191.94M	$185.16M	$110.18M
Total Assets	$1.77B	$1.92B	$683.00M
Current Liabilities	$168.52M	$164.18M	$48.56M
Long-term Debt	$1.25B	$1.20B	$401.13M
Total Liabilities	$1.62B	$1.60B	$525.94M
Stockholders' Equity	($48.20M)	$105.19M	$152.52M
Retained Earnings	($280.19M)	($123.42M)	($6.36M)

Cash Flow

Line item	FY 2022	FY 2021	FY 2020
Operating Cash Flow	$65.37M	$17.05M	$26.69M
Investing Cash Flow	($38.70M)	($779.17M)	($17.08M)
Financing Cash Flow	($15.66M)	$766.14M	$11.40M
CapEx	$44.76M	$17.87M	$13.42M
Free Cash Flow	$20.61M	($817.0K)	$13.27M

Ratios

Metric	FY 2022	FY 2021	FY 2020
Profitability
Gross margin	-	-	-
Operating margin	-3.7%	3.1%	13.9%
EBITDA margin	9.4%	13.8%	22.0%
Net margin	-20.9%	-10.3%	-8.1%
Free cash flow margin	2.7%	-0.2%	5.3%
FCF / Net income	-0.13	0.02	-0.65
R&D / Revenue	-	-	-
SG&A / Revenue	-	-	-
Effective tax rate	-	-	-
Return on assets	-8.9%	-2.3%	-3.0%
Return on equity	325.2%	-41.2%	-13.4%
Return on invested capital	-1.8%	0.8%	5.0%
Liquidity
Current ratio	1.14	1.13	2.27
Quick ratio	1.14	1.13	2.27
Cash ratio	0.35	0.29	0.40
Leverage
Debt / Equity	-26.03	11.39	2.63
Debt / Assets	0.71	0.62	0.59
Debt / EBITDA	17.89	20.66	7.25
Interest coverage	-0.2x	0.2x	1.1x
Equity multiplier	-36.62	18.24	4.48
Liabilities / Assets	0.92	0.83	0.77
Efficiency
Asset turnover	0.42	0.22	0.37
Inventory turnover	-	-	-
Days sales outstanding	56d	105d	120d
Days inventory outstanding	-	-	-
Days payable outstanding	-	-	-
Cash conversion cycle	-	-	-
Valuation
P / E	-	-	-
P / B	-	-	-
P / S	-	-	-
EV / EBITDA	-	-	-
Growth
Revenue growth (YoY)	78.0%	67.6%	-
Revenue CAGR (3y)	-	-	-
Revenue CAGR (5y)	-	-	-
Gross profit growth (YoY)	-	-	-
Operating income growth (YoY)	-	-62.5%	-
Net income growth (YoY)	-262.1%	-112.2%	-
EPS growth (YoY)	-	-	-
EPS CAGR (3y)	-	-	-
EPS CAGR (5y)	-	-	-
FCF growth (YoY)	-	-	-
FCF CAGR (5y)	-	-	-
Book value growth (YoY)	-	-31.0%	-

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2021-12-31.

Business segments

$421.08M total

Radiology$374.40M · 88.9%

Oncology$46.68M · 11.1%

Product / service

$416.07M total

Commercial Revenue$226.84M · 54.5%

Hospital And Healthcare Providers$118.49M · 28.5%

Medicare Revenue$51.24M · 12.3%

Other Patient Revenue$11.50M · 2.8%

Medicaid Revenue$8.00M · 1.9%

Stability scores

Altman Z′

FY 2022 · bankruptcy risk

0.24

Distress

Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.

Piotroski F-score

FY 2022 · 9-point quality

4/9

Neutral

✗Net income positive
✓Operating cash flow positive
✗ROA improved YoY
✓Cash flow > net income
✗Long-term debt decreased
✓Current ratio improved
-No share dilution
-Gross margin improved
✓Asset turnover improved

Peer comparison

Same SIC group: Services-Medical Laboratories

Company	Revenue (last FY)	Net margin	ROE
NTRA	$2.31B	-9.0%	-12.2%
GH	$982.02M	-42.4%	419.2%
LH	$13.95B	6.3%	10.2%
DGX	$11.04B	9.0%	13.8%
CSTL	$344.23M	-7.0%	-5.1%

Comparing AKUMIN INC. against the 5 most active filers in the same SIC group.